*Klebsiella pneumoniae* is a gram-negative bacillus that causes pneumonia, bloodstream infections, and urinary tract infections in hospitalized or immunocompromised patients \[[@CIT0001]\]. It is a leading cause of health care--associated infections (HAIs), causing around 10% of HAIs annually \[[@CIT0002]\]. Additionally, *K. pneumoniae* is becoming increasingly resistant to antibiotics, including carbapenems, complicating treatment of infections and leading the Centers for Disease Control and Prevention to label *Klebsiella* an urgent public health threat \[[@CIT0003]\]. Prior colonization with *K. pneumoniae* is significantly associated with subsequent infection, and 80% of infections in colonized patients are caused by their colonizing strain \[[@CIT0004], [@CIT0005]\]. The acquisition of Carbapenem-resistant *K. pneumoniae* (CRKP) in the hospital is strongly associated with colonization pressure, and cohorting patients colonized with CRKP is more effective at preventing transmission than any other infection control measure alone \[[@CIT0006]\]. Therefore, understanding risk factors for *K. pneumoniae* colonization could direct screening measures to vulnerable patient populations, preventing the spread of colonization throughout the hospital and identifying patients at risk for later infection.

Vancomycin-resistant *Enterococci* (VRE) is a gram-positive coccus that causes around 20~ ~000 HAIs annually. Like *K. pneumoniae,* VRE colonization is a risk factor for later infection \[[@CIT0009], [@CIT0010]\], with a sensitivity of 94%, specificity of 78%, and relative risk of 24.15 for bacteremia \[[@CIT0011]\]. To prevent patient-to-patient spread of VRE, many hospitals perform routine surveillance cultures of rectal swabs and place detectably colonized patients in contact precautions \[[@CIT0012]\]. *K. pneumoniae* and VRE infect a similar patient population of hospitalized, immunocompromised patients, and previous antibiotic exposure is a risk factor for colonization with antibiotic-resistant strains of either organism \[[@CIT0001], [@CIT0013], [@CIT0015]\]. We have previously shown high *K. pneumoniae* colonization rates in patients screened for VRE \[[@CIT0004]\]. Despite colonizing similar patients, the biological and epidemiological links between VRE and *K. pneumoniae* are unclear.

Culturing VRE surveillance samples for *K. pneumoniae* and analyzing patient medical records could identify factors associated with colonization in patients susceptible to infection. Upon patient identification, 1 potential intervention strategy might involve manipulating the microbiota to better resist colonization by exogenous pathogens. Previous studies have begun to identify intestinal microbiota signatures associated with acquisition of VRE and other multidrug-resistant organisms \[[@CIT0016]\]. For example, CRKP colonization has been associated with the presence of 2 specific operational taxonomic units (OTUs; *Desulfovibrio* and *Ruminococcaceae*) \[[@CIT0019]\], but this finding may be specific to the specific *Klebsiella* clone. Identifying species found in the microbiota that are broadly associated with *K. pneumoniae* colonization could enable widely applicable approaches to infection prevention.

The objective of this study was to identify patient factors associated with colonization with *K. pneumoniae* in ICU patients. We screened samples from 2 patient cohorts, 1 from 2014 and 1 from 2016, for *K. pneumoniae* colonization and analyzed the associations between colonization and patient demographics, baseline laboratory data, and comorbidities. In addition, 16S rRNA sequencing of the microbiome was performed to determine if there was a microbiota signature associated with *K. pneumoniae* colonization. Understanding risk factors for *K. pneumoniae* colonization might inform surveillance practices for *K. pneumoniae* colonization in the hospital setting.

METHODS {#s1}
=======

Sample Collection {#s2}
-----------------

This study was conducted at Michigan Medicine, a tertiary care center with 1000 beds, and approved by the Institutional Review Board. Rectal swabs were obtained through Michigan Medicine's VRE surveillance program, wherein adult patients admitted to the intensive care unit (ICU) or hematology/oncology wards have a rectal swab taken upon admission and then weekly until a positive VRE culture is obtained or the patient is discharged. We included swabs collected from adults during 2 time periods: July 31, 2014, to October 31, 2014 (n = 1800), and January 10, 2016, to May 25, 2016 (n = 1824).

Bacterial Identification and Patient Population {#s3}
-----------------------------------------------

Rectal swabs (ESwab Collection and Transport System, Becton Dickinson, Franklin Lakes, NJ, USA) were sent to Michigan Medicine's Clinical Microbiology laboratory and cultured to identify VRE using VRE*Select* chromogenic media (Bio-Rad, Hercules, CA, USA). Swabs were stored in glycerol at --80ºC. To identify *Klebsiella pneumoniae* in the samples, swabs were either cultured on MacConkey agar plates before freezing (2014 cohort) or after thawing (2016 cohort), and 10 μL of sample was streaked. Three mucoid lactose-fermenting colonies were isolated and subcultured onto MacConkey agar plates. If \<3 mucoid lactose-fermenting colonies were present from the sample, then all colonies were subcultured. Matrix-assisted laser desorption ionization--time of flight (MALDI-TOF) analysis was used for bacterial identification from the subcultures. Only patients with rectal swabs screened for both *K. pneumoniae* and VRE that were collected during patients' first encounter with Michigan Medicine during the study periods were included: 1209 for the 2014 cohort and 1243 for the 2016 cohort.

Demographic Definitions {#s4}
-----------------------

Patient electronic medical records (EMRs) were reviewed for patient variables associated with colonization. Comorbidity data were collected from the patient's first encounter during the study. Comorbidities were defined using the Elixhauser Comorbidity Index \[[@CIT0020]\]. The Elixhauser Comorbidity Score was calculated as previously described \[[@CIT0021], [@CIT0022]\]. Antibiotic usage was defined as antibiotic administration that occurred within 30 days preceding rectal swab collection and that started at least 48 hours before rectal swab collection. Patients were considered to have a *K. pneumoniae* clinical culture if their EMRs indicated a positive clinical blood, urine, or respiratory culture for *K. pneumoniae* within 90 days after their first rectal swab. Patients were considered to have a *K. pneumoniae* infection if the clinical culture met case definitions for a bloodstream infection, pneumonia, or a urinary tract infection within 90 days after their first rectal swab. Bloodstream infection was defined as any blood culture positive for *K. pneumoniae.* Pneumonia was defined based on new or progressive radiographic infiltrate plus at least 2 of 3 clinical features (fever \>38ºC, leukocytosis or leukopenia, and purulent secretions) \[[@CIT0023]\]. Urinary tract infection was defined based on National Healthcare Safety Network (NHSN) case definitions \[[@CIT0024]\].

Antibiotic susceptibility results (Sensititre, ThermoFisher Scientific) were extracted for *Klebsiella-*colonized patients with subsequent positive clinical cultures and reviewed for interpretations of extended-spectrum beta-lactamase and carbapenem resistance in the specimen report.

DNA Purification and Microbiota Analysis {#s5}
----------------------------------------

The MagAttract PowerMicrobiome DNA/RNA Kit (Qiagen, Inc., Hilden, Germany) optimized for the EpMotion 5075 (Eppendorf, Hamburg, Germany) was used to isolate DNA from swabs. The V4 region of the bacterial 16S rRNA genes was polymerase chain reaction--amplified \[[@CIT0025]\] from 1 μL of the sample DNA, as previously described \[[@CIT0026]\]. The 500 cycle MiSeq Reagent Kit v.2 (Illumina, catalog No. MS-102-2003) was used to prepare amplicons for sequencing on a MiSeq (Illumina, San Diego, CA, USA) by the University of Michigan Microbial Systems Molecular Biology Laboratory using the manufacturer's protocols \[[@CIT0026]\].

Sequences were quality-trimmed and processed using mothur v.1.39.5 \[[@CIT0027]\] as described previously \[[@CIT0019]\]; chimeras were removed using UCHIME \[[@CIT0028]\] and reads aligned to the SILVA 16S rRNA sequence database \[[@CIT0029]\]. Samples with \<2500 sequences were excluded from further analysis. Using mothur's opticlust algorithm \[[@CIT0030]\], sequences were clustered into OTUs at 97% similarity. The Ribosomal Database Project was used to classify OTUs \[[@CIT0031]\]. Inverse Simpson's index, shared OTUs, and the Yue and Clayton dissimilarity index were calculated from unfiltered OTU data. Principal components analysis and analysis for molecular variance (AMOVA) were calculated in mothur. Basic R packages were used to visualize data. We created Dirichlet multinomial mixture models using R v.3.3.2 and used the DirichletMultinomial v.1.6.0 package \[[@CIT0032]\] to assign all samples to community types, as proposed by Holmes et al. \[[@CIT0033]\]. We determined the number of community types by comparing the Laplace approximation with the negative log posterior likelihood and identifying the point at which an increase in Dirichlet components results in minor improvements in model fit.

Statistical Analysis {#s6}
--------------------

We compared the distributions of continuous variables among *K. pneumoniae--*colonized patients with those of noncolonized patients using the Student *t* test; for categorical variables, we used the chi-square or Fisher exact test. Variables significantly associated with *K. pneumoniae* colonization in either cohort at α = 0.05 were entered into a multivariate logistic model predicting *K. pneumoniae* colonization. Univariate analysis comparing co-colonized, *K. pneumoniae--*colonized, VRE-colonized, and noncolonized patients was conducted using 1-way analysis of variance for continuous variables and the chi-square or Fisher exact test for categorical variables. Additional analyses comparing the colonized groups with the noncolonized group were performed using Tukey's multiple comparisons test for continuous variables and the chi-square or Fisher exact test for categorical variables with the hybrid Wilson/Brown method of estimating confidence intervals (Prism 7, Graph Pad). AMOVA was used to distinguish the microbiota structure between patient groups. The nonparametric Kruskal-Wallis test was used for multigroup microbiota comparisons.

RESULTS {#s7}
=======

VRE Colonization Is Associated With *K. pneumoniae* Colonization {#s8}
----------------------------------------------------------------

Of the 1209 rectal swabs collected from eligible patients between July 31 to October 31, 2014 (2014 cohort), 209 (17.3%) were colonized with *K. pneumoniae.* In the 2016 cohort, collected from 1243 eligible patients between January 10 and May 25, 2016, 91 (7.3%) were colonized with *K. pneumoniae* ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). In addition to increased prevalence of *K. pneumoniae* colonization in 2014 (*P* \< .0001), women represented a higher percentage and white patients represented a smaller percentage of patients. Conversely, length of stay was significantly longer in the 2016 cohort ([Table 1](#T1){ref-type="table"}). Based on significant differences between the cohorts, the results were stratified based on cohort year, with the goal of finding consistent associations across 2 cohorts that differ by date and *K. pneumoniae* colonization rates.

###### 

Demographic Information and Colonization Rates for the 2014 and 2016 Cohort

                                            Year                        
  ----------------------------------------- ------------- ------------- ---------
  Sex--female                               591 (48.9)    548 (44.1)    .017
  Age, mean ± SD, y                         57.9 ± 16.4   58.9 ± 16.4   .119
  Race--white                               990 (81.9)    1059 (85.2)   .028
   Black                                    128 (10.6)    121 (9.7)     
   Other                                    91 (7.5)      63 (5.1)      
  Admits from nursing home                  3 (0.2)       2 (0.2)       .683
  Length of stay, mean ± SD, d              11.5 ± 17.0   13.2 ± 17.4   .017
  Death within 30 d                         110 (9.1)     120 (9.7)     .637
  Elixhauser comorbidity score, mean ± SD   7.22 ± 8.7    6.92 + 7.5    .363
  *Klebsiella pneumoniae--* colonized       209 (17.3)    91 (7.3)      \<.0001
  VRE-colonized                             118 (9.8)     96 (7.7)      .074
  Primary service--surgery                  216 (17.9)    224 (18.0)    .094
   GynOnc                                   117 (9.7)     87 (7.0)      
   Cardiac                                  119 (9.8)     100 (8.1)     
   HemOnc                                   181 (15.0)    194 (15.6)    
   Medical critical care                    78 (6.5)      69 (5.6)      
   Medicine                                 229 (19.0)    249 (20.0)    
   Burn                                     17 (1.4)      13 (1.0)      
   Cardiothoracic surgery                   184 (15.2)    222 (17.9)    
   Other                                    68 (5.6)      85 (6.8)      

Differences between the cohorts were calculated using the Student *t* test for continuous variables and the chi-square or Fisher exact test for categorical variables.

Abbreviation: VRE, vancomycin-resistant *Enterococci*.

To identify variables consistently associated with *K. pneumoniae* rectal colonization, univariate analysis was performed on demographic, comorbidity, and baseline laboratory data from each cohort ([Table 2](#T2){ref-type="table"}). The Elixhauser comorbidity score was not significantly associated with colonization in either cohort (2014: 7.57 ± 8.47 vs 7.14 ± 8.80; *P* = .52; 2016: 7.55 ± 6.37 vs 6.87 ± 7.57; *P* = .40). A positive clinical culture for *K. pneumoniae* was associated with rectal colonization in both the 2014 (odds ratio \[OR\], 5.0; 95% confidence interval \[CI\], 2.82--9.2; *P* \< .0001) and 2016 (OR, 3.5; 95% CI, 1.38--9.07; *P* = .0263) cohorts. The sensitivity of detectable colonization for a subsequent positive culture was 48.9% (95% CI, 35.3%--62.8%) and 20.8% (95% CI, 9.2%--40.5%), and the specificity was 83.9% (95% CI, 81.8%--86.0%) and 92.9% (95% CI, 91.4%--94.3%) in the 2014 and 2016 cohorts, respectively. The negative predictive value for subsequent infection was consistently high in both cohorts (2014: 97.6%; 95% CI, 96.5%--98.4%; 2016: 98.4%; 95% CI, 97.4%--98.9%). We reviewed antibiotic resistance among clinical cultures from *Klebsiella*-colonized patients. Consistent with the low institutional resistance rate for *K. pneumoniae*, 1 extended-spectrum beta-lactamase isolate was found in a 2016 clinical culture, and no CRKP were detected. Clinical infection was significantly associated with *K. pneumoniae* colonization in the 2014 cohort (OR, 5.5; 95% CI, 2.51--12.20; *P* \< .0001). Infections were higher among patients who were colonized with *K. pneumoniae* in the 2016 cohort as well (OR, 2.85; 95% CI, 0.61--11.0); however, this did not reach statistical significance. In the cohort from 2014, patients colonized with *K. pneumoniae* were more likely to be female, have hypertension, have lower baseline albumin levels, and be older than noncolonized patients. In the 2016 cohort, *K. pneumoniae--*colonized patients were more likely to die within 30 days, have a neurologic disorder, and have underlying pulmonary circulation comorbidities. VRE colonization (2014: OR, 1.57; 95% CI, 0.95--2.57; 2016: OR, 2.20; 95% CI, 1.258--3.877) and low albumin baseline (2014: 3.44 ± 0.62 colonized vs 3.56 ± 0.65 not colonized; *P* = .027; 2016: 3.34 ± 0.58 vs 3.47 ± 0.62; *P* = .072) were potential shared risk factors for *K. pneumoniae* colonization between the cohorts.

###### 

Clinical and Demographic Characteristics of Patients With and Without *Klebsiella pneumoniae* Colonization

                                              2014 Cohort   2016 Cohort                                 
  ------------------------------------------- ------------- ------------- --------- ------ ------------ --------
  Female                                      591           116 (19.63)   .035      548    37 (6.75)    .494
  Male                                        618           93 (15.05)              695    54 (7.77)    
  Age                                                                     .024                          .254
   \<50 y                                     347           42 (12.10)              344    21 (6.10)    
   51--60 y                                   275           51 (18.55)              249    14 (5.62)    
   61--70 y                                   306           59 (19.28)              333    26 (7.81)    
   71+ y                                      281           57 (20.28)              317    30 (9.46)    
  Race                                                                    .386                          .119
   White                                      990           169 (17.1)              1059   71 (6.7)     
   Black                                      128           27 (21.1)               121    14 (11.5)    
   Other                                      91            13 (14.2)               63     6 (9.5)      
  Length of stay                                                          .954                          .877
   \<4 d                                      357           63 (17.65)              333    22 (6.61)    
   4--7 d                                     267           48 (17.98)              277    20 (7.22)    
   7--14 d                                    302           52 (17.22)              267    19 (7.12)    
   14+ d                                      283           46 (16.25)              366    30 (8.20)    
  Death in 30 d                               110           23 (20.91)    .292      120    15 (12.50)   .022
  No death in 30 d                            1099          186 (16.92)             1123   76 (6.77)    
  Later *K. pneumoniae* clinical culture      47            23 (48.9)     \<.0001   24     5 (20.8)     .0263
  No later *K. pneumoniae* clinical culture   1162          186 (16.0)              1219   86 (7.1)     
  Later *K. pneumoniae* infection             25            13 (52.0)     \<.0001   11     2 (18.1)     .1897
  No later *K. pneumoniae* infection          1184          196 (16.6)              1232   89 (7.2)     
  VRE-colonized                               96            23 (23.96)    .072      118    16 (13.56)   .006
  Not VRE-colonized                           1113          186 (16.71)             1125   75 (6.67)    
  Neurologic disorder                         95            16 (16.84)    \>.999    65     11 (16.92)   .005
  No neurologic disorder                      1114          193 (17.32)             1178   80 (6.79)    
  Congestive heart failure                    127           25 (19.69)    .457      123    14 (11.38)   .097
  No congestive heart failure                 1082          184 (17.01)             1120   77 (6.88)    
  Pulmonary circulation disorder              72            13 (18.06)    .872      67     10 (14.93)   .026
  No pulmonary circulation disorder           1137          196 (17.24)             1176   81 (6.89)    
  Peripheral vascular disease                 90            20 (22.22)    .194      99     7 (7.07)     \>.999
  No peripheral vascular disease              1119          189 (16.89)             1144   84 (7.34)    
  Hypertension                                449           92 (20.49)    .027      198    10 (5.05)    .233
  No hypertension                             760           117 (15.40)             1045   81 (7.75)    
  Admitted overnight 180 d prior              701           124 (17.69)   .664      676    55 (8.14)    .907
  Not admitted overnight 180 d prior          508           85 (16.73)              567    36 (6.35)    
  Antibiotic exposure                         110           12 (10.91)    .064      170    10 (5.88)    .438
  No antibiotic exposure                      1099          197 (17.93)             1073   81 (7.55)    
  Central line                                92            12 (13.04)    .263      147    7 (4.76)     .205
  No central line                             1117          197 (17.93)             1096   84 (7.66)    
  Urinary catheter                            87            17 (19.54)    .564      136    5 (3.68)     .084
  No urinary catheter                         1122          192 (17.11)             1107   86 (7.77)    
  Hemoglobin baseline                                                     .204                          .554
   \<9.9                                      313           58 (18.53)              319    29 (9.09)    
   10--11.7                                   303           58 (19.14)              316    22 (6.96)    
   11.8--13.4                                 303           55 (18.15)              303    19 (6.27)    
   13.5+                                      288           38 (13.19)              303    21 (6.93)    

Differences between colonized and not-colonized patients were calculated using the Student *t* test for continuous variables and the chi-square or Fisher exact test for categorical variables.

Abbreviations: Kp, *Klebsiella pneumoniae*; VRE, vancomycin-resistant *Enterococci*.

In the final multivariable models, VRE colonization was associated with *K. pneumoniae* colonization with similar point estimates in both cohorts (2014: OR, 1.58; 95% CI, 0.92--2.62; 2016: OR, 2.07; 95% CI, 1.06--3.83), as was age \>70 (OR, 1.73; 95% CI, 1.09--2.78; OR, 1.8; 95% CI, 0.96--3.47) ([Table 3](#T3){ref-type="table"}). Black race (OR, 1.38; 95% CI, 0.85--2.2; OR, 1.91; 95% CI, 0.94--3.63) had similar point estimates in both but did not reach statistical significance in either cohort. In the 2014 cohort, male gender was inversely associated with *K. pneumoniae* colonization (OR, 0.7; 95% CI, 0.51--0.96), but this was not observed in the 2016 cohort (OR, 1.14; 95% CI, 0.71--1.85). Similarly, hypertension was associated with colonization in the 2016 cohort (OR, 0.49; 95% CI, 0.22--0.97), but the point estimate was reversed in the 2014 cohort (OR, 1.33; 95% CI, 0.97--1.83).

###### 

Multivariable Logistic Regression Model for *Klebsiella pneumoniae* Colonization in 2014 and 2016

                                   2014 Cohort         2016 Cohort                        
  -------------------------------- ------------------- ------------- -------------------- -----
  VRE colonization                 1.58 (0.92--2.62)   .08           2.07 (1.06--3.83)    .03
  Male gender                      0.7 (0.51--0.96)    .03           1.14 (0.71--1.85)    .6
  Race (ref. white)                                                                       
  Black                            1.38 (0.85--2.2)    .18           1.91 (0.94--3.63)    .06
  Other                            0.71 (0.27--1.59)   .45           1.29 (0.3--3.88)     .68
  Unknown                          1.13 (0.44--2.55)   .78           2.94 (0.44--11.63)   .17
  Days in hospital                 0.99 (0.98--1)      .22           1 (0.98--1.01)       .6
  Albumin ≤3                       0.95 (0.69--1.31)   .77           0.87 (0.47--1.53)    .64
  Age (ref. \<50 y)                                                                       
   50--60 y                        1.66 (1.04--2.66)   .03           0.84 (0.37--1.84)    .66
   60--70 y                        1.72 (1.1--2.71)    .02           1.17 (0.6--2.31)     .65
   Over 70 y                       1.73 (1.09--2.78)   .02           1.8 (0.96--3.47)     .07
  Death within 30 d                1.25 (0.74--2.05)   .39           1.68 (0.85--3.15)    .12
  Neurologic disorder              1.07 (0.58--1.88)   .81           2.07 (0.9--4.4)      .07
  Pulmonary circulation disorder   0.96 (0.47--1.82)   .91           2.18 (0.95--4.57)    .05
  Hypertension                     1.33 (0.97--1.83)   .08           0.49 (0.22--0.97)    .05

Abbreviations: CI, confidence interval; VRE, vancomycin-resistant *Enterococci*.

VRE Colonization Is Associated With Comorbidities and Poor Outcomes {#s9}
-------------------------------------------------------------------

After establishing the association between *K. pneumoniae* and VRE colonization in ICU patients, we tested the hypothesis that co-colonized patients have more comorbidities and worse health outcomes. We grouped the cohorts into patients colonized with both *K. pneumoniae* and VRE, patients colonized with *K. pneumoniae* or VRE, and patients colonized with neither organism and performed univariate analysis with postanalysis, comparing each colonized group with the noncolonized group (Supplementary [Table 1](#T1){ref-type="table"}). Across both cohorts, the Elixhauser score was higher and albumin baseline was lower in the both-positive and VRE-positive colonization groups compared with the both-negative group. Also in both cohorts, death within 30 days, central lines, and urinary catheters were significantly associated with VRE colonization only, compared with the both-negative group. In the 2014 cohort but not the 2016 cohort, patients colonized with both organisms and only *K. pneumoniae* were more likely to have a later *K. pneumoniae* infection compared with patients colonized by neither. Overall, VRE and dual-colonized patients appeared to have poorer overall health compared with noncolonized patients, whereas *K. pneumoniae*--colonized patients did not.

*Klebsiella* and *Enterococcus* OTUs Dominate the Gut Microbiota in Colonized Patients {#s10}
--------------------------------------------------------------------------------------

The positive association between VRE and *K. pneumoniae* colonization suggested that the microbiota may differ between colonized (either alone or with both) and noncolonized patients. To examine these differences and better understand potential mechanisms of colonization, we performed 16S rRNA gene-based analysis on a total of 248 available rectal swabs from the 2014 cohort. Of those swabs, 7 were from patients co-colonized with VRE and *K. pneumoniae*, 20 were from patients colonized with VRE, 31 were from patients colonized with *K. pneumoniae,* and 190 swabs were from patients not colonized with either organism at baseline.

Overall diversity of the microbiota communities (inverse Simpson's diversity) did not significantly differ across the 4 groups ([Figure 1A](#F1){ref-type="fig"}). However, beta-diversity indices, reflective of microbial community similarity between the groups, demonstrated that co-colonized individuals exhibited a more similar microbiota to *K. pneumoniae*--colonized patients than to VRE-colonized or noncolonized patients ([Figure 1B](#F1){ref-type="fig"}). Further, co-colonized patients and *K. pneumoniae* patients shared more operational taxonomic units (OTUs) than co-colonized patients and VRE-colonized patients ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). AMOVA based on the Yue and Clayton theta dissimilarity index \[[@CIT0034]\] indicated significant differences between groups overall (*P* \< .001) ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}) and between the noncolonized group compared with the co-colonized group (*P* = .048), the VRE-positive group (*P* \< .001), or the *K. pneumoniae*--positive group (*P* \< .001). The community composition also differed significantly between the *K. pneumoniae--* and VRE-colonized groups (*P* = .003) ([Figure 1C](#F1){ref-type="fig"}). Community modeling by Dirichlet multinomial mixtures (DMMs) separated the samples into 4 community state types (CSTs) ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}) \[[@CIT0032], [@CIT0033]\]. Although no single CST was correlated with colonization, patients colonized with any combination of *K. pneumoniae* and VRE were significantly more likely to have CST1 or 2 compared with CST 3 and 4 combined (*P* = .05). Principal coordinate analysis with overlayed biplots of OTUs indicated that 2 OTUs of *Enterobacteriaceae* (OTU1 and OTU2) and 1 *Enterococcus* OTU (OTU3) were strong components in driving these influences ([Figure 1C](#F1){ref-type="fig"}). Further comparisons of the sequences clustered into each of the OTUs revealed that OTU1 contained sequences classified as *Escherichia coli/Shigella*, whereas OTU2 contained *K. pneumoniae, K. variicola,* and *Enterobacter* species. OTU3 contained sequences classifying as *Enterococcus* species. Consistent with numbering convention, these were the most predominant OTUs in these samples.

![A, Alpha diversity (inverse Simpson index) and (B) beta diversity, or community structure similarity (Yue & Clayton dissimilarity) in the microbiota of noncolonized ("negative"), co-colonized ("Kp/VRE(+)"), *K. pneumoniae*--colonized ("Kp(+)"), and VRE-colonized ("VRE(+)") patients (Kruskal-Wallis adjusted with Benjamini-Hochberg method and Dunn's post hoc; \**P* \< .01; ^\*\*^*P* \< .001; ^\*\*\*^*P* \< .0001). C, Principal components analysis of the fecal microbiota community in all 4 patient groups, based on Yue & Clayton dissimilarity (AMOVA, *P* \< .05). Abbreviations: AMOVA, analysis for molecular variance; Kp, *Klebsiella pneumoniae*; VRE, vancomycin-resistant *Enterococci*.](ofaa012f0001){#F1}

We compared the relative abundance of these predominant OTUs in each of the patient groups ([Figure 2](#F2){ref-type="fig"}). The OTU2 containing *Klebsiella* was significantly more abundant in samples from patients colonized with *K. pneumoniae* alone (*P* \< .0001) or co-colonized with VRE (*P* = .013) compared with patients colonized with neither organism. Similarly, *Enterococcus* (OTU3) was higher in samples from patients colonized by VRE (*P* = .0002). OTU1 (containing *E.coli/Shigella* sequences) was less abundant in patients colonized with *K. pneumoniae* compared with no colonization but did not reach statistical significance (*P* = .08). To determine if these dominant OTUs were driving the overall differences observed in the microbiomes based on colonization state, we removed *Klebsiella* OTU2 and *Enterococcus* OTU3 and repeated our analyses. In this modified data set, AMOVA did not detect significant differences between the 4 colonization states (*P* = .182).

![Relative abundance of OTU0001, OTU0002, and OTU0003 in noncolonized ("negative"), co-colonized ("Kp/VRE(+)"), *K. pneumoniae*--colonized ("Kp(+)"), and VRE-colonized patients ("VRE(+)"; Kruskal-Wallis adjusted with Benjamini-Hochberg method and Dunn's post hoc; \**P* \< .01; ^\*\*^*P* \< .001; ^\*\*\*^*P* \< .0001). Abbreviations: Kp, *Klebsiella pneumoniae*; VRE, vancomycin-resistant *Enterococci*.](ofaa012f0002){#F2}

DISCUSSION {#s11}
==========

We and others have shown previously that *K. pneumoniae* colonization is associated with subsequent infection \[[@CIT0004], [@CIT0005]\]. This study sought to identify patient factors associated with *K. pneumoniae* colonization in ICU patients, including VRE colonization, which might be used to target screening programs to patients most likely to benefit from infection prevention interventions. In 2 separate cohorts of 1209 and 1243 patients, the only consistent patient factor associated with *K. pneumoniae* colonization was advanced age. By contrast, colonization with VRE alone or VRE plus *K. pneumoniae* was associated with worse baseline comorbidities than *K. pneumoniae* alone. However, there was an important microbiological factor: VRE colonization was associated with *K. pneumoniae* colonization. Importantly, the differences in the microbiome between groups seem to be driven by *Klebsiella* and *Enterococcus* themselves, with a higher abundance of a *Klebsiella* OTU in *Klebsiella* and co-colonized groups and a higher abundance of an *Enterococcus* OTU in VRE-colonized groups compared with the noncolonized group.

Outcomes of colonization include potential transmission to other patients and increased risk of infection in the colonized patient. This study was not designed to detect transmission, although there are reports of transmission from a colonizing strain from ICU settings across the globe \[[@CIT0004], [@CIT0005]\]. Further, *K. pneumoniae* infections occur frequently in colonized patients, as shown in a previous analysis of the 2014 cohort, where a significant association between infection and colonization was observed \[[@CIT0004]\]. The current analysis using the first collected rectal swabs from each patient's first hospital encounter and their fecal microbiome demonstrated the same association with subsequent *Klebsiella* clinical cultures.

The consistent association between VRE and *K. pneumoniae* colonization has several implications. Because VRE status is routinely determined in units with an active surveillance program, detectable VRE colonization could be used to identify patients who are potentially colonized with *K. pneumoniae*. As a biological implication, this association suggests that VRE and *K. pneumoniae* interact in the fecal microbiome. Unlike infections caused by other health care--associated pathogens, such as *Clostridium (Clostridioides)difficile* \[[@CIT0035]\], we did not observe differences in the overall diversity of the microbiota across the patient groups. This suggests that *K. pneumoniae* does not require a depauperate microbiome, lacking in number and variety of species, to persist and may be found in the range of intestinal microbial communities seen in this hospital. VRE has similar dynamics, although it tends to colonize patients with more comorbidities than *K. pneumoniae*.

Our microbiota analysis also indicates that *K. pneumoniae* and *Enterococcus* are predominant taxa in the microbiome of ICU patients. Intestinal domination with *Enterococcus* and CRKP is associated with subsequent infections \[[@CIT0036], [@CIT0037]\]. Data from our study indicate that detectable colonization may represent dominance of that taxa in the microbiome, and not simply its presence, perhaps explaining why detectable colonization with VRE or *K. pneumoniae* is also associated with subsequent infection.

A previous study demonstrated that CRKP and VRE neither compete nor synergize in the murine model, and the 2 organisms reside within the same intestinal regions but occupy distinct metabolic niches \[[@CIT0038]\]. Further, different indigenous OTUs classified as Enterobacteriaceae in mice impact susceptibility to another enteric pathogen, *Salmonella* \[[@CIT0039]\]. It is possible that similar mechanisms in humans exist, where 1 endogenous, nonpathogenic organism can confer protection against other similar organisms.

A strength of this study was the use of 2 large cohorts of patients separated over time with extensive available chart data and known VRE and *K. pneumoniae* colonization status. VRE colonization was associated with *K. pneumoniae* colonization in each cohort despite significant differences in overall *K. pneumoniae* colonization rates between cohorts. An intriguing possibility is that these differences in colonization rates may be related to differences in ambient temperature between the summer of 2014 and winter of 2016 ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). *K. pneumoniae* bacteremia rates are highly correlated with temperature \[[@CIT0040]\]. Perhaps this fluctuation is due to changing colonization rates that in turn affect infection rates. The significant differences in demographics and overall comorbidities between cohorts were both a strength and a limitation, highlighting the robust association between *K. pneumoniae* and VRE but perhaps confounding identification of other variables associated with colonization.

In summary, this study demonstrates a reproducible association between detectable VRE and *K. pneumoniae* colonization and suggests that each can colonize varied intestinal microbial communities found in hospitalized patients.

Supplementary Data {#s12}
==================

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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Click here for additional data file.
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